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Abstract
Background:  Females with the neurological disorder Rett syndrome are heterozygous for
mutations in X-linked MECP2 that encodes methyl-CpG binding protein 2 (MeCP2) thought to act
as a transcriptional repressor. To identify target genes for MeCP2 modulation, we studied global
gene expression in single cell-derived wild-type and mutant MECP2 expressing fibroblast clones
with four common mutations (R106W, R306C, 705delG, 1155del32) and in lymphoblastoid cell
lines (LCLs) that included four mutant MeCP2 (T158M, 803delG, R168X and 1159del28)
expressing, and five (1159del28, R106W, R255X, 803delG, 803delG) wild-type MeCP2 expressing
lines.
Methods: Clonality and mutation status were verified by androgen receptor methylation assays
for X-inactivation and by sequencing MECP2 transcripts. Expression studies were done with
oligonucleotide microarrays (Affymetrix U95) and verified with real-time quantitative RT-PCR
using Sybr Green.
Results:  Expression of 49 transcripts was increased, and expression of 21 transcripts was
decreased, in at least 3 of 4 mutant/wild-type fibroblast comparisons. Transcript levels of 11 genes,
determined by quantitative RT-PCR, were highly correlated with the microarray data. Therefore,
multiple additional clones from two Rett individuals were tested by RT-PCR only. Striking
expression differences were found in both mutant and wildtype MeCP2 expressing clones.
Comparing expression profiles of lymphoblastoid cell lines yielded 16 differentially expressed
genes.
Conclusions: MeCP2 deficiency does not lead to global deregulation of gene expression. Either
MeCP2's in vivo function does not involve widespread transcriptional repression, or its function is
redundant in cell types that also express other methyl-CpG binding proteins. Our data suggest that
clonal fibroblast strains may show substantial inter-strain variation, making them a difficult and
unstable resource for genome-wide expression profiling studies.
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Background
Rett syndrome (OMIM # 312750  [http://www.nc-
bi.nlm.nih.gov/Omim/]) is an X-linked dominant disor-
der that occurs with a prevalance of 1 in 10,000 to 15,000
births [1] and almost exclusively in females. Named after
Andreas Rett who first recognized the disorder in 1966
[2], the syndrome is characterized by a constellation of
clinical findings that have resulted in the establishment of
clinical criteria for the diagnosis [3]. Common clinical fea-
tures include early normal development until approxi-
mately 6–18 months of age followed by a period of
developmental stagnation and subsequent regression,
usually by 3 years of life. Characteristic findings include
loss of speech and motor skills, deceleration of head
growth, stereotypic hand movements, seizures, respirato-
ry abnormalities, scoliosis and growth delay. Although
the disorder is usually sporadic, due to new mutations, a
few familial cases permitted exclusion mapping on the X
chromosome with assignment of the responsible gene to
band Xq28 [4–6].
Mutations in MECP2, the gene that encodes the DNA
binding protein MeCP2 (methyl-CpG binding protein 2),
have been found in approximately 65–77% of Rett syn-
drome patients [7–10]. The functional consequence of
MECP2 mutations resulting in Rett syndrome is loss of
function. Three of the four MECP2 exons encode a 486
amino acid protein that is believed to be a transcriptional
repressor based on in vitro studies. MeCP2's functional
structure consists of an 84 amino acid methyl-binding do-
main (MBD) [11] and a 104 amino acid transcriptional
repression domain (TRD) [12]. The MBD is able to bind
to 5-methyl cytosine residues of a single CpG dinucleotide
[11]. Under the current model, MeCP2 binds to DNA,
then complexes with Sin3A through the TRD and recruits
histone deacetylases (HDAC). Deacetylation of core his-
tones then alters chromatin structure and results in tran-
scriptional repression [13,14].
While MeCP2 is a ubiquitously expressed protein, its ex-
pression is highest in the brain, lung and spleen and less
abundant in the kidney and heart [15,16]. It's cellular lo-
calization is also specific, with expression in neurons but
not in glia. Expression levels in brain increase postnatally
[16]. These findings explain why the most prominent clin-
ical features of Rett syndrome are related to central nerv-
ous system (CNS) dysfunction. The presence of growth
retardation [17], osteopenia [18], and gastrointestinal ab-
normalities, however, suggest a potentially important role
for MeCP2's function in the peripheral and autonomous
nervous system and in other tissues. Alternatively, while
MeCP2's expression is ubiquitous, other methyl-CpG
binding proteins that exist within complexes, MBD1 and
MBD2 [19] or Kaiso [20], may reduce the effect of muta-
tions in MECP2 in peripheral organ systems while the lack
of such redundancy may lead to a more pronounced phe-
notype in the brain. This theory remains speculative, how-
ever, since the tissue specificity and definitive
identification of functional redundancy of methyl-CpG
binding proteins have not been established. Regardless,
the targets of MeCP2 modulation remain unknown in the
brain or elsewhere.
To identify potential downstream targets of MeCP2 mod-
ulation, we have compared global gene expression pat-
terns in four matched pairs of clonally derived mutant or
wild-type MECP2-expressing fibroblast cell strains from
girls with Rett syndrome, and in five wild-type and four
mutant MeCP2-expressing lymphoblastoid cell lines, by
hybridizing Affymetrix U95 (A-E) oligonucleotide micro-
arrays. The use of clonally derived fibroblasts eliminated
the mosaic X inactivation seen in tissues from most fe-
males with Rett syndrome. Furthermore, expression pat-
terns in clones with the mutant MECP2 allele active were
compared with those in clones with the wild-type allele
on the active X chromosome. Because both types of clones
are derived from the same individual, variability intro-
duced by differences in autosomal genetic background is
eliminated by our experimental strategy. The use of lym-
phoblastoid cell lines, while not all clonally derived, ex-
panded the scope of genes to be assayed beyond those
expressed in skin fibroblasts. Our interrogations identi-
fied a statistically significant number of genes with differ-
ential expression patterns between wild-type and mutant
cell strains, however, the results across multiple clones
from the same individual showed substantial variability,
questioning the significance of some of the genes identi-
fied. The lymphoblasts, while not analysed in a matched
comparison, yielded a relatively short list of genes with
differential expression that includes some potentially in-
teresting candidate genes.
Methods
Cell culture, single cell cloning and nucleic acid extraction 
for fibroblasts
Four fibroblast strains from females with clinically diag-
nosed Rett syndrome were obtained from Coriell Cell Re-
positories. MECP2 mutations were identified in our
laboratory as previously reported [10] [GM07982:
705delG; GM11270: 916C>T (R306C); GM11272:
1155del32 and GM11273: 316C>T (R106W)]. From each
of the four cultures, single-cell derived clonal cell strains
were established. To do so, fibroblasts were trypsinized
(0.05%) (GibcoBRL Life Technologies) and diluted to 100
cells/ml. By using a 125 µm Stripper™ Tip (MidAtlantic
Diagnostics, Marlton, NJ) under direct microscopic visual-
ization, individual cells were transferred to 96 well plates.
Cells were grown with filtered (0.2 µm) conditioned me-
dium that was prepared by culturing the primary cell
strain for two days during the exponential growth phaseBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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in MEM-alpha (Sigma, St. Louis, MO) with 15% fetal calf
serum (Gemini, Woodland, CA), penicillin (100 U/ml),
streptomycin (100 µg/ml), and glutamine (290 ng/ml)
(GibcoBRL Life Technologies). Upon confluency of the
well, the cells were trypsinized and expanded. Growth
rates and cellular morphology were closely monitored.
Only clonal cell strains in the exponential growth phase
with similar cell and clonal morphology were selected for
further study. RNA was extracted using RNA STAT-60 (Tel-
Test Inc., Friendswood, TX) from eight 150 mm plates of
exponentially growing sub-confluent cells that were at
similar passage numbers. DNA was extracted from two ad-
ditional 150 mm plates using a standard extraction proto-
col to determine X chromosome inactivation status and
verify monoclonality.
Cell culture, single cell cloning and nucleic acid extraction 
for lymphoblasts
Clonal cell lines with the mutant MECP2 allele on the ac-
tive X chromosome were derived from lymphoblastoid
cell lines (LCLs) from four females with clinically diag-
nosed Rett syndrome and known mutations (T158M,
803delG, R168X) [10] and 1159del28 (unpublished) us-
ing the technique described above. Individual cells were
cultured in conditioned RPMI 1640 medium with 15% fe-
tal calf serum, penicillin (100 U/ml), streptomycin (100
U/ml) and glutamine (290 ng/ml). Four cell lines from fe-
males with known MECP2 mutations (R106W, R255X,
and two with 803delG) but completely skewed X chromo-
some inactivation with the wild-type MECP2 allele on the
active X chromosome were also cultured. In addition, one
clonal cell line with the wild-type MECP2 allele on the ac-
tive X chromosome was established using the cloning
technique described above. RNA was extracted using RNA
STAT-60 (Tel-Test Inc., Friendswood, TX). DNA was ex-
tracted using a standard extraction protocol to determine
X chromosome inactivation status and verify mono-
clonality.
X chromosome inactivation studies
Clonality was further confirmed and X chromosome inac-
tivation status was determined by the length of the poly-
morphic CAG trinucleotide repeat on the inactive
androgen receptor allele [21,22]. Restriction digestion of
four restriction sites between the flanking primers and ad-
jacent to the trinucleotide repeat were carried out with the
methylation sensitive enzymes HpaII and HhaI. Amplifi-
cation of the undigested allele that included the trinucle-
otide repeat region was performed using the fluorescent-
labeled primer 5'-6FAM CTGTGAAGGTTGCTGTTCCT-
CAT-3' and the unlabeled primer 5'-TCCAGAATCTGTTC-
CAGAGCGTGC-3'. The lengths of the amplification
products were identified using the ABI 377 sequencer with
the GeneScan™ fragment analysis software (Applied Bio-
systems, Foster City, CA). Undigested DNA samples from
each of the original cell cultures were amplified to deter-
mine the lengths of each allele.
Allele-specific MECP2 transcript analysis
Reverse transcription of 2 µg of total RNA was performed
after Dnase I digestion (Roche Diagnostics, Indianapolis,
IN) with the Superscript™ II RNase H-Reverse Tran-
scriptase (GibcoBRL Life Technologies) protocol for
cDNA synthesis using 500 ng of random hexamers. Ab-
sence of DNA contamination was verified by amplifica-
tion of the intron containing region of the MECP2 gene
between exons 3 and 4 using exon 3 based primer 5'-
AGCCCGTGCAGCCATCAGCC-3' and exon 4 based prim-
er 5'-CTTCCCAGGACTTTTCTCCA-3'. The regions con-
taining the mutations were amplified by PCR using
primers and conditions previously described [7] and later
modified [23]. PCR products were treated with 1 U exonu-
clease and 1 U shrimp alkaline phosphatase for 15 min at
37°C. The enzymes were heat inactivated at 75°C for 15
minutes. Both strands of the treated PCR product were se-
quenced with fluorescent labelled terminator nucleotides
on the ABI PRISM®377 DNA sequencer. Cell clones ex-
pressing only the mutant MECP2 allele are called "mutant
clones", and cell clones or skewed cell lines expressing
only the normal MCP2 allele are called "wild-type".
Immunoblot analysis with MeCP2 antibody
MeCP2 protein expression in fibroblast clones and lym-
phoblastoid cell lines was determined by immunoblot
analysis. Cells were washed twice with PBS and lysed with
RIPA buffer (1% Triton X-100, 1% NaDOC, 0.1% SDS,
158 mM NaCl, 10 mM Tris pH 7.2, 5 mM NaEDTA and
1% protease inhibitors, added just before use) (Sigma, St.
Louis, MO). The homogenate was sonicated, followed by
centrifugation at 4°C for 30 min. The supernatant was
saved for immunoblot. Equal quantities of protein, as de-
termined by a protein assay (BioRad, Hercules, CA), were
separated by electrophoresis in a 12% SDS-polyacryla-
mide gel. The gel was then equilibrated in transfer buffer
for 15 min and transferred to a polyvinylidine difluoride
membrane (Novex, San Diego, CA), also equilibrated in
transfer buffer for 15 min, for 1 hr at 100 V. The mem-
brane was blocked overnight with 5% non-fat milk in PBS
at 4°C, and incubated with a rabbit polyclonal antibody
(1:2000) against a peptide (CPRPNREEPVDSRTP) at the
C-terminal region of MECP2 (Upstate Biotechnology,
Lake Placid, NY) at room temperature for 2 h in a western
wash solution (PBS containing 2% non-fat milk, 0.1%
Tween 20, and 350 mM NaCl). The membrane was
washed in the same solution and then incubated with a
horseradish peroxidase conjugated secondary antibody
(1:5000) in the same solution for 30 min. The membrane
was subsequently washed again, and bound antibody was
detected with an ECL kit (Amersham, Piscataway, NY).BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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Affymetrix oligonucleotide array (GeneChip®) hybridiza-
tion
Messenger RNA was purified from total RNA extract using
theOligotex™ batch protocol (Qiagen, Valencia, CA). The
SuperScript™ Choice System was used for (ds)-cDNA syn-
thesis (GibcoBRL Life Technologies) using the T7-(dT)24
primer 5'-GGCCAGTGAATTGTAATACGACTCACTATAG-
GGAGGCGG-(dT)24-3' and 3 µg of mRNA for each reac-
tion. Biotin-labeled in vitro transcription (IVT) was
accomplished with the Enzo BioArray™ High Yield™ tran-
script labeling kit (Affymetrix, Santa Clara, CA) using 4 µl
of (ds)-cDNA product. IVT cleanup was performed using
Rneasy® Columns (Qiagen, Valencia, CA). The IVT prod-
uct was chemically fragmented with 40 mM Tris-acetate,
pH 8.1, 125 mM KOAc and 30 mM MgOAc at 94°C for 35
minutes. The fragmented product was hybridized to the
Affymetrix GeneChip® Human Genome U95 Set (A-E)
(Affymetrix, Santa Clara, CA).
Quality control parameters were assessed throughout the
experimental process to assure the quality of the starting
RNA, the efficiency of transcription, integrity of hybridiza-
tion, and consistency of qualitative calls. Assessment dur-
ing the synthesis of the hybridization transcript was
accomplished by spectrophotometric analysis of the start-
ing RNA and cRNA and gel electrophoresis following syn-
thesis of the cDNA, cRNA and fragmentation of the cRNA.
A 3'/5' ratio of GAPDH less than 2 was considered accept-
able for efficiency of transcription. Spiked control tran-
scripts were also monitored to verify hybridization
integrity. Scaling factors for each sample ranged between
0.88 and 17.8 with the ratio of scaling factors between
samples for a given chip ranging from 1.4 to 2.5. All qual-
ity control measures were consistent with the manufactur-
ers recommended procedures and conformed to the
recommended cut-off values.
Microarray data analysis for fibroblast clones
All GeneChips® were analyzed using MicroArray Suite
3.0™ (MAS 3.0) with target intensities normalized to
2500. Baseline genetic expression profiles of one clonal
wild-type MeCP2-expressing fibroblast strain were com-
pared to the expression profile of the matched clonal mu-
tant MeCP2-expressing cell strain, for each of four
different MECP2 mutations. Analyzed data were imported
to MicroDB™ and queried using Affymetrix's Data Mining
Tool (DMT). All four matched pair comparisons were
queried for directional changes. For genes/ESTs with in-
creased levels of expression, defined by MAS 3.0 as mar-
ginally increased or increased, wild-type baseline
expression levels could be present or absent. For genes
with decreased levels of expression, defined by MAS 3.0 as
marginally decreased or decreased, wild-type baseline ex-
pression levels were required to be present. We identified
genes that demonstrated the same directional change in at
least three of four comparisons. We computed p values for
genes identified by this criterion. We assumed that if a
gene was not subject to a systematic change in expression
level, an observed directional change in a given mutant
strain would occur randomly and independently with
probability equal to the overall proportion of directional
changes observed in that mutant strain. We used one-sam-
ple, two-sided t-tests on the reported GeneChip® fold
changes to assess whether the log fold changes of mutant
cell strains differ from zero on average. We report the cor-
responding 95% confidence intervals (CI) after conver-
sion back from the log scale. Although the assumptions of
the t-test cannot be verified, there was insufficient data to
carry out alternative tests.
Microarray data analysis for lymphoblastoid cell lines
All GeneChips® were analyzed using MAS 3.0 with target
intensities normalized to 2500. Only one lymphoblast
cell line yielded both a clonal wild-type and clonal mu-
tant cell line (1159del28). Baseline expression profiles
were derived from the clonal wild-type cell line
(1159del28), and the four completely skewed wild-type
Figure 1
MECP2 transcript sequence and GeneScan™ results for the
human androgen receptor (AR) polymorphism used to
determine X chromosome inactivation patterns. A. Parental
cell strain with 916C>T (R306C) mutation and mosaic X-
inactivation with expression of 285 bp and 288 bp AR alleles.
B. Fibroblast clone from R306C donor expresses MECP2
transcript with mutant T allele and carries the 288 bp AR
allele on the inactive X chromosome. C. Fibroblast clone
from R306C donor expresses MECP2 transcript with normal
C allele and carries the 285 bp AR allele on the inactive X
chromosome.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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cell line controls (R106W, R255X, 803delG, 803delG).
Expression profiles from the mutant clonal cell line
(1159del28) and three additional clonal mutant MeCP2
expressing cell lines (T158M, 803delG, R168X) were com-
pared to the baseline expression profiles. Each mutant ex-
pression profile was compared to each wild-type control
profile yielding 20 comparisons. Analyzed data was im-
ported to MicroDB™ and queried using DMT. All 20 com-
parisons were queried to identify genes that demonstrated
similar directional changes in at least 15 of 20 unmatched
pair comparisons (four mutant samples compared indi-
vidually to each of five wild-type samples). For genes with
increased levels of expression, defined by MAS 3.0 as mar-
ginally increased or increased, wild-type baseline expres-
sion levels could be present or absent. For genes with
decreased levels of expression, defined by MAS 3.0 as mar-
ginally decreased or decreased, wild-type baseline expres-
sion levels were required to be present. We used two-sided
Wilcoxon rank-sum tests on the reported uncompared
values for the two groups to test whether the expression
profiles of mutant cell lines differ from those of wild-type
cell lines.
Real-time comparative quantitative PCR
Total RNA from the four matched pairs of clonal fibrob-
last cell strains and ten lymphoblast cell lines used on the
GeneChips® was used as template for RT-PCR to inde-
pendently assess the validity of Affymetrix GeneChip® da-
ta. Each RT reaction was performed with RNA from the
same preparation used for the GeneChip® hybridization.
Total RNA from eight additional clonal cell strains (four
mutant and four wild-type) with the R106W mutation
and fourteen additional clonal cell strains (seven mutant
and seven wild-type) with the 1155del32 mutation were
also used as template for RT-PCR to assess consistency of
results across different clonal fibroblast cell strains. Re-
verse transcription of total RNA was performed after
Dnase I digestion (Roche Diagnostics, Indianapolis, IN)
with the Superscript™ II Rnase H-Reverse Transcriptase
(GibcoBRL Life Technologies) protocol for cDNA synthe-
sis using 2 µg of total RNA and 1 µg of random hexamers.
Absence of DNA contamination was verified by amplify-
ing the 756 bp intron containing region of the MECP2
gene between exons 3 and 4 using exon 3 based primer 5'-
AGCCCGTGCAGCCATCAGCC-3' and exon 4 based prim-
er 5'-CTTCCCAGGACTTTTCTCCA-3'. Minus RT samples
tested simultaneously with experimental samples by
quantitative RT-PCR with Sybr® Green consistently yield-
ed no amplification below 33 cycles using the above pro-
tocol. The RT product was diluted 10 fold, aliquoted and
stored at -80°C. Forward and reverse primers were de-
signed using Applied Biosystem's Primer Express v1.0™
software (Applied Biosystems, Foster City, CA) from con-
sensus sequences provided by Affymetrix  [http://
www.netaffx.com] for each gene of interest. Each 25 µl
PCR mix contained 7.875 µl Sybr® Green Master Mix (1X
Sybr® Green Buffer, 3 mM MgCl2, 200 nM dNTP blend,
0.6275 U Amplitaq Gold®, 0.25 U AmpErase® UNG),
200–400 nM forward and reverse primers and approxi-
mately 5 ng template. Cycle conditions for the ABI 7700
were 50°C for 2 minutes, 95°C for 10 minutes and 35 cy-
cles of 95°C for 15 sec and 60°C for 1 minute. The average
of four endogenous controls (GAPDH, β actin, TATA IID
and transferrin) was used to normalize the amount of
template for each wild-type and mutant pair. Each reac-
tion was run in triplicate with the results averaged on the
log (base 2) scale. Standard curves for each amplification
product were generated from 10-fold dilutions of pooled
cDNA to determine primer efficiency. Data was analyzed
with Microsoft Excel 2000 to generate raw expression val-
ues.
We performed paired t-tests on the RT-PCR values for the
original set of fibroblast clones to test whether the average
log change across cell strains differs from zero. We used
unpaired t tests for the second set of fibroblast clones
from each of two cell strains to determine whether multi-
ple clones from individuals undergo a systematic fold
change. We used unpaired Wilcoxon rank-sum tests for
the lymphoblast cell lines to test whether there is a sys-
tematic fold change across lines. All reported 95% confi-
dence intervals are reported in terms of fold changes, but
derived from t-tests computed on the log scale.
Results
Characterization of clonal cell strains
Clonal mutant and wild-type MECP2 expressing fibrob-
last cell strains were successfully established from four
Rett females with different mutations, one missense in the
MBD, one missense in the TRD and two frameshift muta-
tions leading to premature stop codons. Clonality was es-
tablished by three independent methods: visualization of
each cell transferred for clonal culture, X inactivation pat-
tern analysis of the polymorphic androgen receptor alleles
using GeneScan™, and identification of single-allele
MECP2 transcripts (Fig. 1).
The levels of MECP2 transcripts were virtually identical by
real-time quantitative RT-PCR analysis (less than 0.27 cy-
cle thresholds difference) across all eight clones, one wild-
type and one mutant from each individual, that were used
for oligonucleotide array hybridization (data not shown).
This result is not surprising. Given the fact that the prema-
ture termination codons resulting from the frameshift
mutations are all located in the 3' final exon of the MECP2
gene, preferential degradation of nonsense codon-con-
taining transcripts would not be expected [24].
To assess MeCP2 expression at the protein level, immuno-
blot analysis with an antibody against the C-terminal re-BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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gion of MeCP2 was carried out on total cell lysates from
all eight fibroblast clones, and from some of the LCLs,
that were used for array hybridization (Fig. 2). A reacting
protein band (at the molecular weight of 75 kD, as indi-
cated by the company,  [http://www.upstate.com]) was
seen in wild-type cell lines expressing a normal sized
MeCP2 protein, and in cell lines with missense mutations
(FB R106W, FB R306C and LCL T158M). Cell clones ex-
pressing an allele with a truncating mutation (FB
705delG, FB 1155del32, LCL R168X), do not produce a
normal sized MECP2 protein. Due to the location of the
epitope, the antibody would not react with putative trun-
cated proteins. The bands seen at approximately 48 and
100 kD are unidentified proteins that cross-react with the
MeCP2 antibody. The absence of a normal sized MeCP2
protein in mutant clones with truncating mutations con-
firms their purity, and, together with the presence of
MeCP2 in the wild-type clones, validates these matched
pairs of cell cultures as a useful experimental system for
the search of downstream effects of MeCP2 deficiency.
Oligonucleotide array hybridization data of matched fi-
broblast clones
The percent "present" calls ranged from 13% (chip D) to
55% (chip A). Standard deviations for the percent
"present" calls for a given chip were 1–3%. There were no
significant differences in percent "present" calls between
MeCP2-deficient and MeCP2-positive samples. A total of
252,700 comparisons (four Rett females × 63,175 interro-
gations on five GeneChips®) revealed 6,745 increased (or
marginally increased) genes/ESTs and 6,966 decreased (or
marginally decreased) genes/ESTs. The number of genes
with increased (+) and decreased (-) levels of expression
in mutant MeCP2 over wild-type expressing clones dif-
fered among the fibroblast strains studied (R106W: 889+,
3056-; R306C: 1700+, 1435-; 705delG: 1160+, 1240-;
1155del32: 2996+, 1235-). The unadjusted p value for
any one gene that was increased (decreased) in three out
of four matched pair comparisons was .000060
(.000075). The p value for any gene that increased (de-
creased) in all four comparisons was 3.29 E-07 (4.72 E-07).
Forty-six genes showed increased levels of expression in
mutant cells in three out of four comparisons. Three genes
were increased in all four comparisons. Of the 49 genes,
29 had been annotated as known genes and 20 as un-
known transcripts. Of those, 7 were found to encode
known genes by searching recent database releases and
the Celera database (Table 1). Expression levels of two
genes (VSHK1 and CA12), represented twice on the chips
with different accession numbers, were increased in both
cases. Of the 47 unique genes with increased transcript
levels in MeCP2 deficient cells, 32 are known to be ex-
pressed in brain (Table 1).
Twenty-one genes demonstrated decreased levels of ex-
pression in three out of four matched comparisons. Of the
21 genes, 13 had been annotated as known genes and 8 as
unknown transcripts, of which one was found to encode
a known gene by searching recent database releases and
Figure 2
Immunoblots of total cell lysates from wild-type (WT) and mutant (M) fibroblast clones and lymphoblastoid cell lines used for
the oligonucleotide expression array hybridization studies. MeCP2 expression is detected with a C-terminal antibody; the
molecular weight of MeCP2 is shown as 75 kDa, consistent with the company's information  [http://www.upstate.com]. In
mutant cell lines with nonsense mutations (FB 705delG, FB 1155del32, and LCL R168X), an intact MECP2 protein is not seen.
Brain lysate from mice and normal human male lymphoblastoid cells serve as positive controls.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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the Celera database (Table 2). Oligonucleotide probes for
two of the genes (COMP and IGFBP5) were represented
twice on the chips, and both genes were detected as show-
ing differential expression. Of the 19 unique genes with
decreased expression in MeCP2 deficient cells, 12 are
known to be expressed in brain (Table 2).
Table 1: Genes with increased levels of expression in at least 3 of 4 mutant MeCP2 expressing clonal fibroblast cell strains when com-
pared to matched clonal wild type MeCP2 expressing cell strains
GenBank Accession Expression In Brain Gene Symbol/
UniGene No.
Gene Name Function
J00123 x HUMENK2 Human enkephalin gene neuropeptide
AW007146 x SYTL2 Synaptotagmin-like 2 neurotransmission
AF051850 SVIL Supervillin link between cytoskeleton and membrane
AA447177 Hs.202101 Beta syntrophina cytoskeletal protein
M13509 x MMP1 Matrix metalloproteinase 1 (interstitial collagenase) breakdown of extracellular matrix
X05232 MMP3 Matrix metalloproteinase 3 (stromelysin 1, progelati-
nase)
breakdown of extracellular matrix
X07820 MMP10 Matrix metalloproteinase 10 (stromelysin 2) breakdown of extracellular matrix
AB011153 x PLCB1 Phospholipase C, beta 1 (phosphoinositide-specific) phospholipase
M72393 PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-depend-
ent)
phospholipase
AW015590 x RGC32 RGC32 protein extracellular matrix protein
AW007426 x SPON2 Spondin 2, extracellular matrix protein extracellular matrix protein
AA401504 VSHK1 Orphan seven-transmembrane receptor, chemokine 
related
chemokine receptor
AI131555 VSHK1 Orphan seven-transmembrane receptor, chemokine 
related
chemokine receptor
AF037335 x CA12 Carbonic anhydrase XII zinc metalloenzyme
AI050855 x CA12 Carbonic Anhydrase XIIa zinc metalloenzyme
AI681917 x Hs.3321 Iriquois related homeobox 3 related proteina transcription factor
AF047419 x TCF21 Transcription factor 21 transcription factor
U01244 x FBLN1 Fibulin 1 secreted glycoprotein (extracellular matrix)
X60708 x DPP4 Dipeptidylpeptidase IV membrane glycoprotein
M14058 x C1R Complement component 1, r subcomponent serine protease (complement pathway)
X90392 x DNASE1L1 Deoxyribonuclease I-like 1 DNAse
Y17782 HSBP3 Heat shock 27 kD protein 3 heat shock protein
AF058056 SLC16A7 Solute carrier family 16 (monocarboxylic acid transport-
ers), member 7
monocarboxylate transport family member
X04430 IL6 Interleukin 6 (interferon, beta 2) induces maturation of B cells
U81607 x AKAP12 A kinase (PRKA) anchor protein (gravin) 12 kinase anchor protein
D28915 x MTAP44 Interferon-induced, hepatitis C-associated microtubular 
aggregate protein
member of interferon inducible proteins
M34057 x LTBP1 Latent transforming growth factor beta binding protein 1 assembly of TGF beta
AL050227 x Hs.27860 Prostaglandin E2 receptor, EP3 Subtypea prostaglandin receptor
W31022 x Hs.48376 TRADEbetaa tumor necrosis factor signaling
AI669308 x BID BH3 interacting domain death agonist cell death regulation
W95076 Hs.271639 RSK-like proteina signal transduction
AI752682 x NTN4 Netrin 4 leukocyte adhesion
M97935 x STAT1 Signal transducer and activator of transcription 1, 91 kD signal transduction
AI338491 Hs.209209 CALD 1 – caldesmon 1a cytoskeletal regulator
M33197 x GAPDH Glyceraldehyde-3-phosphate dehydrogenase carbohydrate metabolism
AA625449 x Hs.238532 N-acetylgalactosaminyltransferase 7a glycosylation
AI189112 x Hs.65366
AI809872 x Hs.19669
AI949749 Hs.44441
AI884906 x Hs.111164
AI984197 x Hs.16064
AI307802 x Hs.135560
AI806221 x Hs.38022
AI018671 Hs.93701
N48346 x Hs.125489
AA426500 Hs.85989
N40767 Hs.6786
AB002365 x Hs.23311
AL080058 x Hs.6909
aIdentified in Celera databaseBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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Quantitative real-time RT-PCR analyses of fibroblast 
clones
To assess the reliability of the array hybridization results,
transcript levels of 11 differentially expressed genes (8
with increased and 3 with decreased expression) were
quantified using real-time quantitative RT-PCR analysis
with Sybr Green®. The same RNA samples used for making
array hybridization probes were used as templates for RT-
PCR. The Pearson correlation coefficient was 0.96 for the
RT-PCR values from triplicate assays. The fold change data
from the GeneChips® and RT-PCR analyses (Table 3) were
converted to log scale for analysis and comparison. The
correlation of the combined RT-PCR fold change data
(based on average of log of the three measurements from
each wild-type and each mutant sample) with the Gene-
Chip® log fold change data was .92 (95% CI = 0.86, 0.96)
(Fig. 3).
Table 2: Genes with decreased levels of expression in at least 3 of 4 mutant MeCP2 expressing clonal fibroblast cell strains when com-
pared to matched clonal wild type MeCP2 expressing cell strains
GenBank Accession Expression In 
Brain
Gene Symbol/
UniGene No.
Gene Name Function
AC003107 COMP Cartilage oligomeric matrix protein extracellular matrix protein
L32137 COMP Cartilage oligomeric matrix protein extracellular matrix protein
U59289 x CDH13 Cadherin 13, H-cadherin cell adhesion
X53586 x ITGA6 Integrin, alpha 6 cell adhesion
AI815057 KLF5 Kruppel-like factor 5 transcriptional regulation of cel-
lular proliferation
D43969 x RUNX1 Runt-related transcription factor 1 transcription factor
L27560 x IGFBP5 insulin-like growth factor binding protein 5 growth homeostasis
AW022852 x IGFBP5 insulin-like growth factor binding protein 5 growth homeostasis
AI433710 x Hs.25557 plasma-cell membrane glycoprotein PC-1a nucleotide phosphatase
AA142891 x P4HA2 prolyl 4-hydroxylase (alpha subunit)a hydroxylase
U38810 x MAB21L1 Mab-21-like eye and cerebellum development
Y00815 x PTPRF protein tyrosine phosphatase, receptor type, 
F
cell signaling
AI017574 x CRIP1 Cysteine-rich protein 1 zinc carrier protein
AI862775 x Hs.66915 sphingolipid G-protein-coupled receptor, 5a endothelial differentiation
AL035494 Hs.184736
AI125670 x Hs.16346
AI718385 x Hs.302738
AI818579 Hs.121520
AI597757 Hs.207407
AI935827 Hs.169758
AB018289 Hs.49500
aIdentified in Celera database
Figure 3
Correlation between GeneChip® and RT-PCR data for
fibroblast clones. Data are log base 2 fold changes for each
mutant/wild-type pair. RT-PCR values are average log
expression levels from triplicate reactions for each clone. X
and Y axes are log fold change values.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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To assess the consistency of differential gene expression
among a larger number of independently derived cell
clones from the same individual, we selected five genes
with large fold change values that had been identified by
microarray analysis and confirmed by RT-PCR. Three
genes with increased expression in mutant clones
(MTAP44, MMP3 and NTN4) and two with decreased ex-
pression (CRIP1 and COMP) were quantitatively tested in
multiple clonal cell strains from two Rett females (with
MECP2 mutations 1155del32 and R106W) using RT-PCR.
Expression levels varied significantly from clone to clone
and between cell strains (Fig. 4). Fold change values for
the multiple clone comparisons were mostly inconsistent
with the original GeneChip/RT-PCR data. Furthermore,
the 95% confidence interval for fold change included 1.0
(no change) in six of the ten comparisons (Fig. 5). Expres-
sion of CRIP1 was significantly different between wild-
type and mutant clones for both Rett individuals tested (p
= 0.004 and p = 0.035), however, the direction of change
was different. Increased expression of only one gene,
MTAP44, encoding the interferon-inducible microtubular
aggregate protein 44, remained significant in comparison
of the mutant and wild-type clones for both individuals
tested (p = 0.027 and p = 0.01) (Fig. 5).
Oligonucleotide array hybridization data of lymphoblasts
The global gene expression pattern in fibroblasts is limit-
ed, and single cell cloning may amplify stochastic events
in culture that may be responsible for the wide range of
transcript levels in fibroblast clones. We, therefore, ex-
tended the microarray analyses to lymphoblastoid cell
lines (LCLs) and studied four clonal mutant MeCP2
(T158M, 803delG, R168X and 1159del28) expressing and
one clonal (1159del28) and four completely skewed
(R106W, R255X, 803delG, 803delG) wild-type MeCP2
expressing LCLs. The percent "present" calls ranged from
13% (chip D) to 50% (chip A) and, as for the fibroblast
data, standard deviations for the percent "present" calls
Table 3: Comparisons of GeneChip® and RT-PCR expression fold changes in mutant versus wild-type MECP2 expressing clones for 11 
differentially expressed genes
Fold Changes for Paired Comparisons
Gene Symbol/
Unigene No.
Method 705delG R306C 1155del32 R106W p value
INCREASED
MMP3 GC 0.91 5.80 31.50 3.90 0.113
RT 0.89 4.81 11.63 3.49 0.094
FBLN1 GC 2.00 11.80 2.00 0.37 0.228
RT 2.03 15.87 2.97 0.72 0.199
SLC16A7 GC 1.80 1.40 2.30 0.77 0.210
RT 1.30 1.69 1.76 0.94 0.112
MTAP44 GC 1.00 2.40 6.10 3.50 0.081
RT 1.36 4.77 20.10 24.15 0.058
LTBP1 GC 1.20 1.30 2.10 2.00 0.047
RT 1.36 3.25 3.59 2.16 0.029
NTN4 GC 3.20 5.50 15.10 3.80 0.016
RT 2.30 2.10 9.80 3.10 0.039
Hs.19669 GC 2.00 2.20 1.90 1.40 0.008
RT 1.22 1.60 2.07 1.30 0.040
Hs.23311 GC 5.90 0.12 2.60 4.40 0.609
RT 3.00 0.23 1.86 11.79 0.467
DECREASED
COMP GC 0.28 0.37 0.02 0.10 0.045
RT 0.18 0.25 0.05 0.09 0.011
KLF5 GC 0.53 0.42 0.56 0.27 0.014
RT 0.63 0.29 1.25 0.42 0.157
CRIP1 GC 0.32 2.80 0.11 0.50 0.347
RT 0.20 2.81 0.10 0.42 0.284
P-values correspond to t-tests of whether average log fold change across the 4 different sets of matched clones differs from zero GC = GeneChip, 
RT = RT-PCRBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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Figure 4
Expression levels of five genes in additional fibroblast clones, not used for GeneChip studies, from two Rett individuals. Left:
seven mutant and seven wild-type MeCP2 expressing clonal fibroblast cell strains with the 1155del32 mutation. Right: four
mutant and four wild-type MeCP2 expressing clonal fibroblast cell strains with the R106W mutation. Expression values are raw
numbers generated from RT-PCR and are for comparative purposes only.
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for a given chip were 1–3%, and differences in percent
"present" calls between wild type samples compared to
mutant samples were not significant. When the expres-
sion profile of each mutant was compared to that of each
wild-type LCL, 16 genes were found to be differentially ex-
pressed in at least 15 of 20 comparisons (Table 4). Eleven
genes showed increased levels of expression, and 5
showed decreased expression. Of those 16 genes, 12 are
annotated as known genes and 9 are expressed in brain.
Quantitative RT-PCR was performed on four genes (three
with increased and one with decreased expression) to as-
sess the accuracy of GeneChip results. In a plot similar to
that shown in Figure 3, the correlation of the combined
RT-PCR fold change data with the GeneChip® log fold
change data was 0.91 (data not shown).
Discussion
Random X inactivation patterns are characteristic for Rett
syndrome that is caused by heterozygosity for mutations
in the X-linked locus MECP2. Our study design was in-
tended to take advantage of the mosaic X chromosome in-
activation in cell strains of Rett syndrome females. From
four original fibroblast samples, we generated clonally de-
rived cell strains that expressed only the mutant MeCP2 or
Figure 5
Ranges of fold changes, determined by quantitative RT-PCR for five genes, in multiple clonal cell strains from two Rett individ-
uals (Statistical analysis of the data shown in Fig. 4). Dark bars represent comparisons of 7 wild-type and 7 mutant MeCP2
expressing clones from the 1155del32 mutation carrier. Open bars represent comparisons of 4 wild-type and 4 mutant MeCP2
expressing clones from the R106W mutation carrier. The lengths of the bars indicate the 95% confidence interval of the fold
change in the log scale. The average estimated fold changes are identified by vertical lines (1.0 represents no change). P values
are unpaired for the difference between the wild-type and mutant clones. Numbers at the bottom indicate log scale.
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only the wild-type MECP2 allele, but not both. We hy-
pothesized that the effects of MeCP2 dysfunction in the
mutant clonal cell strain would be more pronounced than
in the original cell strain with mosaic X chromosome in-
activation. Moreover, we were able to establish the ideal
matched control for each clonal mutant cell strain, a clon-
al cell strain with the wild-type MECP2 allele on the active
X chromosome from the same individual. Comparative
transcription profiling of matched pairs of fibroblast
clones should eliminate any noise contributed by poly-
morphisms or mutations of autosomal genes.
Although MeCP2 expression is higher in other tissues
such as brain, spleen and lung [16], the value gained by
the matched pair comparisons of clonal skin fibroblast
strains cultured under identical environmental condi-
tions, should overcome the drawbacks of evaluating a tis-
sue with a lower level of expression. Previously reported
microarray studies of female Rett and unrelated control
brain samples revealed expression changes that were inter-
preted as secondary to the disease process, such as in-
creased expression of glial-specific genes and decreased
expression of neuronal genes [25]. Therefore, when
searching for the primary targets of MeCP2 modulation, it
might be advantageous to study a tissue that is less obvi-
ously involved in the pathologic processes of the disease.
To identify potential target genes of MeCP2 regulation, we
looked for genes with increased transcript levels in at least
three out of four mutant/wild-type MECP2 expressing fi-
broblast comparisons. Similarly, genes with decreased ex-
pression in at least three out of four matched pair
comparisons were also considered potential targets of
MeCP2 regulation. If the calls made did not reflect real in-
creases or decreases, we would expect expression level in-
creases and decreases to be scattered randomly
throughout the 63,175 transcripts interrogated. By ran-
dom chance alone, we would expect to see fewer than four
genes increased in three of four comparisons and fewer
than one (0.03 genes) increased in four of four compari-
Table 4: Genes with increased and decreased levels of expression in at least 15 of 20 comparisonsbetween 4 mutant MeCP2 expressing 
LCLs and 5 wild type MeCP2 expressing LCLs
INCREASED
GenBank Accession Expression In 
Brain
Gene Symbol/
UniGene No.
Gene Name Function
X15306 x NF-H Neurofilament H intermediate filament
J03600 x ALOX5 Arachidonate 5-lipoxygenase synthesis of leukotrienes
M38690 CD9 CD9 antigen (p24) transmembrane protein
J04076 x EGR2 Early growth response 2 transcription factor
AA873858 x H2BFD H2B histone family, member D compaction of DNA
M81750 MNDA Myeloid cell nuclear differentiation 
antigen
cell specific response to interferon
S81914 IER3 Immediate early response 3 inhibits apoptosis
M33197 x GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase
carbohydrate metabolism
AI761588 Hs.359719
AF052145 x Hs.159528
AB020695 x Hs.91662
DECREASED
GenBank Accession Expression In 
Brain
Gene Symbol/
UniGene No.
Gene Name Function
L08177 EBI2 Epstein-Barr virus induced gene 2 G-protein coupled receptor
AW026672 TXNIP Thioredoxin interacting protein upregulated by 1,25-dihydroxyvitamin D-3
AI239716 Hs.344976 Chloride intracellular channel 2 
proteina
anion transport
AI290954 x Hs.110080 Alpha-2-macroglobina cell growth
AI431931 x Hs.128797
aIdentified in Celera databaseBMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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sons. The number of differentially regulated genes identi-
fied by these criteria, 49 with increased and 21 with
decreased expression, is significantly higher than expected
by random chance, but it is much lower than one would
expect if MeCP2 had a crucial role as transcriptional re-
pressor of all genes with methylated promoters.
To validate the microarray expression data with an inde-
pendent method, we carried out real-time quantitative RT-
PCR analyses for a sub-set of 11 genes on all 8 samples
that were used on the GeneChips®. The results were amaz-
ingly consistent for fold change and direction of change in
almost all instances. We, therefore, chose to use quantita-
tive RT-PCR alone to assess whether the increased or de-
creased expression patterns observed in the initial four
matched pairs of clones were consistent in other clones
and, therefore, might be biologically meaningful. Much to
our surprise, expression levels of 5 genes in 11 additional
MeCP2-deficient and 11 additional MeCP2-positive
clones from two Rett individuals, one with a missense and
one with a truncating mutation, showed tremendous var-
iation. In the multiple clone comparisons, the fold change
values trended away from the significant fold changes
seen on the GeneChips® and RT-PCR of the original
matched pair comparisons toward 1.0 (no change).
CRIP1 expression generated significant p values, but the
direction of change differed in the two individuals tested.
In the truncating mutation 1155del32, expression was de-
creased and in the missense mutation R106W, it was in-
creased. Although individual background genetic
differences between the two Rett females might be respon-
sible for these results, the possibility that the opposite
type changes are mutation-type specific needs to be evalu-
ated by studies of clones from additional patients.
Only MTAP44, encoding the interferon-inducible micro-
tubular aggregate protein 44, remained significant in com-
parison of the mutant and wild-type clones, with average
increases of 3.12 and 5.58 fold, for the two individuals
tested. The product of this gene was first identified by a
monoclonal antibody against microtubular aggregates in
hepatocytes of chimpanzees infected with hepatitis C vi-
rus [26]. The production of p44 mRNA is markedly in-
duced in the liver of chimpanzees infected with hepatitis
C or hepatitis D virus [27]. Inducibility by interferon-al-
pha/beta, but not by interferon-gamma, is mediated by an
interferon-stimulated response element in the promoter
region [27]. The gene was independently identified in a
search for novel interferon-inducible genes in the mouse
(Dron, M., Meritet, J.F. and Tovey, M.G. unpublished,
GenBank # AJ299405). Also known as IFI44 (for Interfer-
on-inducible protein 44), the human gene is located on
chromosome 1p31.1. Although predominantly expressed
in uterus and other internal organs, transcripts have been
isolated from brain and hypothalamus cDNA libraries
(see dbEST). The putative function of this protein in the
brain is still a mystery.
A different design was used for the microarray study of
Rett syndrome LCLs. We initiated the LCL study because
MeCP2 protein expression was higher in lymphoblasts
than in fibroblasts, and LCLs have an overlapping expres-
sion pattern that includes genes not expressed in fibrob-
lasts. Because of skewed X inactivation in the available
LCLs, however, we were only able to obtain one matched
pair of mutant versus wild-type expressing clones (for
1159del28). For the 20 different comparisons, we includ-
ed three mutant-allele expressing clones (T158M,
803delG, R168X) and four completely skewed wild-type
MeCP2 expressing LCLs (R106W, R255X, 803delG,
803delG) from different donors. Nevertheless, only 16
differentially expressed genes were identified, with a sub-
set confirmed by quantitative RT-PCR. None of these
genes were identical to any candidates found in the fi-
broblast study. Gene expression patterns in primary fi-
broblasts and transformed lymphoblasts are different
and/or may respond differently to MeCP2 deficiency. Sev-
eral of the candidate targets identified in lymphoblasts
that are also expressed in brain (Table 4) may warrant fur-
ther evaluation.
While our initial matched fibroblast clonal comparisons
identified numerous genes with consistent results that
could be targets of MeCP2 modulation, verification of a
small subset of these data by comparing additional clones
not used on the GeneChip® analysis revealed amazing in-
consistency. The variability of gene expression across
clonal cell strains with the same genotype and the same X
chromosome active was similar among clones expressing
the mutant or the wild-type MECP2 allele. Therefore, it is
not likely to result from MeCP2 dysfunction and we can
exclude the possibility that MECP2 mutations lead to
transcript instability. More likely, fibroblasts in culture
undergo random modification of gene expression, by so-
matic mutations or epigenetic regulation, and such rare
events may be amplified in single-cell derived clones. In
uncloned fibroblast populations, RNA samples from rep-
licate cultures revealed consistent results in comparative
large-scale gene expression studies [28]. Cell lines, i.e.
transformed, immortalized or tumor-derived cell lines,
are well known to be heteroploid i.e. chromosomally un-
stable, and any single-cell derived clones of such lines are
genetically heterogeneous. Therefore, some differences in
transcript levels among such clones would not be surpris-
ing. There are almost no reports in the literature, however,
on comparative gene expression studies in clones of pri-
mary fibroblasts. One of the reasons may be that it is dif-
ficult to generate such clones. In 1981, Griffin et al [29]
reported variation in the activity of steroid 5alpha reduct-
ase, the enzyme that converts testosterone to dihydrotes-BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/12
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tosterone, in cloned human skin fibroblasts. Activity of
this enzyme is low in non-genital skin but high in genital
skin cells that grow in response to androgen. Foreskin-de-
rived fibroblast clones varied greatly (up to 200 fold) in
enzyme activity. The range of activity for other microsom-
al enzymes was much lower in the same fibroblast clones.
These authors did not study mRNA levels but reductase ac-
tivity, therefore, variation at the level of protein stability
could also play a role.
Our data could be interpreted to suggest that microarray
experiments should be performed on greater numbers of
samples and/or samples from mutant and wild-type brain
to generate meaningful data. It is instructive, however,
that Tudor and colleagues compared global gene expres-
sion in a large number of wild-type and Mecp2-null male
mice and failed to identify striking changes in gene expres-
sion in the brain [30].
Conclusions
Both fibroblast and lymphoblast data together agree in
the most important positive result of our studies: MeCP2
deficiency does not result in global deregulation of gene
expression. This result is novel and unexpected in light of
the purported function of MeCP2 as a global transcrip-
tional regulator that was based on in vitro biochemical
studies. There are several possibilities that might explain
our findings. First, redundancy in methyl-CpG binding
proteins that recruit transcriptional silencing complexes
may mask the effects of MeCP2 deficiency; for example,
MBD1, MBD2 or Kaiso, may complement the defect in the
cell types we studied. Second, if the inter-clonal variation
we detected by the quantitative RT-PCR study of 5 genes
in 22 clones from two different Rett individuals were rep-
resentative of a general feature of diploid fibroblast
clones, it could have masked any consistent biologically
meaningful expression changes. If our limited findings
were confirmed by larger-scale studies, we would need to
conclude that clonal fibroblast strains are not a suitable
resource for genome-wide expression profiling studies.
Third, deregulation of very few genes expressed only in
parts of the brain, or only under certain conditions, may
be responsible for the neuronal abnormalities in Rett
brains, and this would not be detected by microarray stud-
ies. Fourth, MeCP2 action on chromatin, as suggested by
observed changes in histone acetylation [31,32], may not
involve protein coding genes that are represented on
microarrays, but instead, may affect centromeric hetero-
chromatin or the expression of small non-coding RNAs
that are abundant in normal brain [33]. The results pre-
sented in this paper contradict the established model of
MeCP2 function and necessitate a rethinking of strategies
to unravel the pathologic process that leads to neuronal
dysfunction in Rett syndrome.
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